Article Sidebar
Main Article Content
Six-Month Outcomes of Endoscopic Intragastric Balloon Therapy: A Prospective Single-Center Study
Main Article Content
Abstract
Background/Aims: Obesity is a growing global health challenge associated with increased morbidity and mortality. Intragastric balloon therapy has emerged as a minimally invasive alternative for weight management in patients unsuitable for bariatric surgery or as a bridging intervention. This study evaluates the efficacy, safety, and metabolic impacts of intragastric balloon therapy in a prospective cohort.
Materials and Methods: A total of 65 patients underwent endoscopic intragastric balloon therapy between October 2023 and January 2025. Comprehensive baseline evaluations included body weight, body mass index, and computed tomography analysis of visceral and subcutaneous fat tissue thickness. Patients were followed up at 2 and 6 months post procedure. Statistical analysis was performed to assess weight loss, metabolic changes, and safety outcomes.
Results: Of the initial cohort, 62 patients (mean age: 37.89 years; 75.4% female) completed the study. The median body weight decreased significantly from 104.5 kg pre-procedure to 88 kg at 6 months (P < .001). Body mass index values similarly declined, with a mean reduction from 37.59 to 32.79 kg/m2 (P < .001). Significant decreases in subcutaneous and visceral fat tissue thickness were observed (P < .001 and P = .032, respectively). Only 1 patient (1.5%) required early balloon removal due to nausea, with no other major complications reported.
Conclusion: Intragastric balloon therapy is an effective and safe intervention for short-term weight loss, with significant reductions in adipose tissue. Further research is needed to evaluate its long-term efficacy and metabolic benefits.
Cite this article as: Yüksel M, Kenarlı K, Sarıaltın F, et al. Six-month outcomes of endoscopic intragastric balloon therapy: A prospective single-center study. Turk J Gastroenterol. Published online May 20, 2025. doi 10.5152/tjg.2025.24043
Article Details
References
1. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10. [CrossRef]
2. Estivaleti JM, Guzman-Habinger J, Lobos J, et al. Time trends and projected obesity epidemic in Brazilian adults between 2006 and 2030. Sci Rep. 2022;12(1):12699. [CrossRef]
3. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363(23):2211-2219. [CrossRef]
4. Jirapinyo P, Hadefi A, Thompson CC, et al. American Society for Gastrointestinal Endoscopy–European society of gastrointestinal endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity. Gastrointest Endosc. 2024;99(6):867-885.e64. [CrossRef]
5. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Circulation. 2014;129(25)(suppl 2):S102-S138. [CrossRef]
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. [CrossRef]
7. Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198-1225. [CrossRef]
8. Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep. 2021;9:23247096211051919. [CrossRef]
9. Grönroos S, Helmiö M, Juuti A, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss and quality of life at 7 years in patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2021;156(2):137-146. [CrossRef]
10. Eisenberg D, Shikora SA, Aarts E, et al. American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Berlin: Springer; 2022.
11. Neylan CJ, Dempsey DT, Tewksbury CM, Williams NN, Dumon KR. Endoscopic treatments of obesity: a comprehensive review. Surg Obes Relat Dis. 2016;12(5):1108-1115. [CrossRef]
12. Saber AA, Shoar S, Almadani MW, et al. Efficacy of first-time intragastric balloon in weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2017;27(2):277-287. [CrossRef]
13. Chan DL, Cruz JR, Mui WL, Wong SKH, Ng EKW. Outcomes with intra-gastric balloon therapy in BMI< 35 non-morbid obesity: 10-year follow-up study of an RCT. Obes Surg. 2021;31(2):781-786. [CrossRef]
14. Kotinda APST, de Moura DTH, Ribeiro IB, et al. Efficacy of intragastric balloons for weight loss in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2020;30(7):2743-2753. [CrossRef]
15. Genco A, Cipriano M, Materia A, et al. Laparoscopic sleeve gastrectomy versus intragastric balloon: a case-control study. Surg Endosc. 2009;23(8):1849-1853. [CrossRef]
16. Diab AF, Sujka JA, Mattingly K, et al. The battle of endoscopic bariatric therapies for obesity: endoscopic sleeve gastroplasty versus endoscopically inserted intragastric balloon—A pairwise meta-analysis of comparative studies and a call for randomized controlled trials. Surg Laparosc Endosc Percutan Tech. 2024;34(6):638-646. [CrossRef]
17. Spyropoulos C, Katsakoulis E, Mead N, Vagenas K, Kalfarentzos F. Intragastric balloon for high-risk super-obese patients: a prospective analysis of efficacy. Surg Obes Relat Dis. 2007;3(1):78-83. [CrossRef]
18. Haddad AE, Rammal MO, Soweid A, et al. Intragastric balloon treatment of obesity: long-term results and patient satisfaction. Turk J Gastroenterol. 2019;30(5):461-466. [CrossRef]
19. Galanakis CG, Daskalakis M, Manios A, Xyda A, Karantanas AH, Melissas J. Computed tomography-based assessment of abdominal adiposity changes and their impact on metabolic alterations following bariatric surgery. World J Surg. 2015;39(2):417-423. [CrossRef]
20. Roman S, Napoléon B, Mion F, et al. Intragastric balloon for “nonmorbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14(4):539-544. [CrossRef]
21. Yorke E, Switzer NJ, Reso A, et al. Intragastric balloon for management of severe obesity: a systematic review. Obes Surg. 2016;26(9):2248-2254. [CrossRef]
22. Kim SH, Chun HJ, Choi HS, Kim ES, Keum B, Jeen YT. Current status of intragastric balloon for obesity treatment. World J Gastroenterol. 2016;22(24):5495-5504. [CrossRef]
23. Goldberg I, Yang J, Nie L, et al. Safety of bariatric surgery in patients older than 65 years. Surg Obes Relat Dis. 2019;15(8):1380-1387. [CrossRef]
24. Francisco CPD, Ravi R, Lopez-Nava G, Asokkumar R. Endoscopic tips for intragastric balloon use for obesity: what you need to know [video]. VideoGIE. 2024;9(10):460-462. [CrossRef]
25. Tahtacı M, Yıldırım E, Üçbilek E, et al. Perception and attitude of Turkish gastroenterologists toward obesity: A nationwide survey conducted by the Obesity Study Group of the Turkish Gastroenterology Association. Turk J Gastroenterol. 2024;35(3):161-167. [CrossRef]